Phaseline

Targets › CD205

CD205 (Lymphocyte antigen 75): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen-processing compartment (By similarity). Causes reduced proliferation of B-lymphocytes. (UniProt, O60449)

Open in Phaseline: the race on CD205, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Oxford BioTherapeuticsOBT076
anti-CD205 antibody-drug conjugate
CD205Phase 1Solid TumorDec 2026

Conditions

Solid Tumor (1)

Modalities

antibody (1)

Companies

Oxford BioTherapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.